Antisense inhibitors of the human immunodeficiency virus

Details Antisense inhibitors of the human immunodeficiency virus Antisense inhibitors of the human immunodeficiency virus

1992-03-18

1997-01-07

Guzo, David

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

4352402, C12N 510, C12N 1563, C12P 2100

Patent

active

055916007

ABSTRACT:
Methods for modulating the expression of the HIV tat gene are disclosed comprising contacting tat RNA with oligonucleotide or oligonucleotide analog which can bind with at least a portions of the RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind to portions of the tat RNA which are of significance to the expression of the gene coding for said RNA. In accordance with a preferred embodiment, methods of treatment of human immunodeficiency virus are disclosed.

REFERENCES:
patent: 4806463 (1989-02-01), Goodchild et al.
Stein et al. "Antisense Oligonucleotide as Theapeutic Agents-Is the Bullet Really Magical", Science, vol. 261, 20 Aug. 1993, pp. 1004-1012.
Johnston et al. "Preent Status and Future Prospects for HIV Therapies" Science, vol. 260, 28 May 1993, pp. 1286-1293.
Antiviral Agents Bulletin, "Discouraging News and Trends", Jan. 1992, vol. 5, No. 1.
Stein & Cohen, "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review," Cancer Research, 48:2659-2668 (1988).
Walder, "Antisense DNA and RNA: progress and prospects," Genes & Development, 2:502-504 (1988).
Marcus-Sekura, "Techniques for Using Antisense Oligodeoxyribunucleotides to Study Gene Expression," Anal. Biochemistry, vol. 172, 289-295 (1988).
Zon, "Synthesis of Backbone-Modified DNA Analogues for Biological Applications," Journal of Protein Chemistry, 6:131-145 (1987).
Van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," BioTechniques, 6:958-973 (1988).
Loose-Mitchell, "Antisense nucleic acids as a potential class of pharmaceutical agents," TIPS, vol. 9, pp. 45-47 (1988).
Goodchild et al., "Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA, 85:5507 (1988).
Agrawal et al., "Inhibiton of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues," Proc. Natl. Acad. Sci. USA, 86:7790 (1989).
Sarin et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," Proc. Natl. Acad. Sci. USA, 85:7448 (1988).
Matsukura et al., "Phosphorothioate analogs of oligodeoxynucleotids: Inhibitors of replication and cytopathic effects of human immunodeficiency virus," Proc. Natl. Acad. Sci. USA, 84:7706 (1987).
Mori et al., "Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity, " Nucleic Acids Res., 17:8207 (1989).
Agrawal et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Nat'l. Acad. Sci. USA, 85:7079 (1988).
Zaia et al., "Inhibition of Human Immunodeficiency Virus by Using an Oligonucleoside Methylphosphonate Targeted to the tat-3 Gene," J. Virol., 62: 3914 (1988).
Letsinger et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture," Proc. Natl. Acad. Sci. USA, 86:6553 (1989).
Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives," Nucl. Acids Res., 17:239 (1989).
Sharp and Marciniak, "HIV Tar: An RNA Enhancer?" Cell 59:229 (1989).
Henthorn, et al., "Expression of a human placental alkaline phosphatase gene in transfected cells: Use as a reporter for studies of gene expression," Proc. Natl. Acad. Sci. USA 85:6342 (1988).
Buck, et al., "Phosphate-Methylated DNA Aimed at HIV-1, RNA Loops and Integrated DNa Inhibits Viral Infectivity," Science 248:208-212 (1990).
Laspia, et al., "HIV-1 Tat Protein Increases Transcriptional Initiation and Stabilizes Elongations," Cell 59:283 (1989).
Garcia, et al., "Human Immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation," EMBO J. 8:765 (1989).
Haseltine and Wong-Staal, "The Molecular Biology of the AIDS Virus," Scientific American Oct., 52 (1988).
Berkhout, "Tat Trans-Activates the Human Immunodeficiency Virus through a Nascent RNA Target," Cell 59:273 (1989).
Stevenson and Iversen, "Inhibition of Human Immunodeficiency Virus Type 1-mediated Cytopathic Effects by Poly(L-lysine)-conjugated Synthetic Antisense Oligodeoxyribonucleotides," J. Gen. Virol. 70:2673 (1989).
Feng and Holland, "HIV-1 tat trans-activation requires the loop sequence within tar," Nature, 334:165 (1988).
G. Zon, "Olizonucleotide Analogues as Potential Chemotherpeutic Agents", Pharmaceutical Res. vol. 5, No. 9, 1988, pp. 539-549.
Zamecrube et al., "Inhibition of Regulation and Expression of Human T-Cell Lymphatopc Virus Type III in Cultured Cells by Exogenous Synthetic Oligonucleotides Complementary to Virual RNA", PNAS, vol. 83, Jun. 1986, pp. 4143-4146.

Affiliated with

Also associated with

Rating

Antisense inhibitors of the human immunodeficiency virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense inhibitors of the human immunodeficiency virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense inhibitors of the human immunodeficiency virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1763270